2020
Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature
Oren-Shabtai M, Kremer N, Lapidoth M, Sharon E, Atzmony L, Nosrati A, Hodak E, Mimouni D, Levi A. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature. Drugs & Aging 2020, 38: 125-136. PMID: 33230804, DOI: 10.1007/s40266-020-00823-5.Peer-Reviewed Original ResearchConceptsOlder patientsBullous pemphigoidTopical corticosteroidsCohort studyTreatment of bullous pemphigoidSide effect profileRetrospective cohort studyNational Institutes of Health databaseProspective cohort studySystematic reviewBackgroundBullous pemphigoidRandomized controlled trialsSignificant adverse effectsPartial responseSystemic corticosteroidsCase seriesTherapeutic optionsPatient selectionTreatment modalitiesAdverse eventsOlder adultsConclusionsCurrent dataPrimary outcomeSecondary outcomesUS National Institutes
2019
Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy
Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, Choate KA. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal Of The American Academy Of Dermatology 2019, 82: 123-131. PMID: 31449901, PMCID: PMC7039698, DOI: 10.1016/j.jaad.2019.08.043.Peer-Reviewed Original ResearchConceptsPorokeratosis lesionsPorokeratosis palmaris et plantaris disseminataPathogenesis-directed therapyTreatment of porokeratosisWeeks of therapyInitiation of therapyPathway gene mutationsDisseminated superficial actinic porokeratosisPathogenesis-based therapiesCase series designSuperficial actinic porokeratosisAdverse eventsTopical therapyTherapeutic optionsComplete clearanceLinear porokeratosisPatientsActinic porokeratosisTherapyPorokeratosisLesionsGene mutationsModerate improvementLovastatinToxic metabolites